Stocks

What's Next For Ionis Pharmaceuticals Stock After A 14% Fall?

The stock price of Ionis Pharmaceuticals (NASDAQ:IONS), a biotech company that specializes in discovering and developing RNA-targeted therapeutics, plunged 14% in yesterday’s trade to its five year low levels of $30, while it is down 19% over the last one month. The recent decline can be attributed to negative data around Tofersen – an experimental drug being jointly developed by Ionis and Biogen for patients with amyotrophic lateral sclerosis (ALS). The drug failed to reach its primary goal in late stage clinical trials, and this didn’t sit well with the investors, resulting in a sharp decline for IONS stock in yesterday’s trade. Note that earlier this year, IONS stock tumbled after Roche decided to halt clinical trials of Tominersen – which was being developed by Ionis and Roche to treat Huntington’s disease.

Now, is IONS stock poised to see lower levels or is a rise imminent? Based on our machine learning analysis of trends in the stock price over the last ten years, there is a higher chance of a rise in IONS stock in the near term. See our analysis on Ionis Pharmaceuticals Stock Return for more details.

1D: IONS -14%, vs. S&P500 0.3%; Underperformed market

(Extremely rare event)

  • Ionis Pharmaceuticals stock dropped 14% on 10/18/2021, compared to broader market (S&P500) rise of 0.3%
  • A change of -14% or more over one trading day is an extremely rare event, which has occurred 4 times out of 2516 in the last 10 years.

10D: IONS -6.4%, vs. S&P500 4.3%; Underperformed market

(24% likelihood event; 53% probability of rise over next 10 days)

  • Ionis Pharmaceuticals stock declined 6.4% over the last ten trading days (two weeks), compared to broader market (S&P500) rise of 4.3%
  • A change of -6.4% or more over ten trading days is a 24% likelihood event, which has occurred 602 times out of 2516 in the last 10 years
  • Of these 602 instances, the stock has seen a positive movement over the next ten trading days on 322 occasions
    This points to a 53% probability for the stock rising over the next ten trading days

21D: IONS -19%, vs. S&P500 1.3%; Underperformed market
(8% likelihood event; 62% probability of rise over next 21 days)

  • Ionis Pharmaceuticals stock declined 19% the last twenty-one trading days (one month), compared to broader market (S&P500) rise of 1.3%
  • A change of -19% or more over twenty-one trading days is a 8% likelihood event, which has occurred 193 times out of 2516 in the last 10 years
  • Of these 193 instances, the stock has seen a positive movement over the next twenty-one trading days on 120 occasions
    This points to a 62% probability for the stock rising over the next twenty-one trading days
 Johnson & Johnson vs. Regeneron Pharmaceuticals.

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.

Trefis  Market-Beating Portfolios Trefis  Price Estimates

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

IONS ARWR

Other Topics

US Markets Investing

Latest Stocks Videos

Trefis

Trefis is an interactive financial community structured around trends, forecasts and insights related to some of the most popular stocks in the US. Whereas most finance sites simply give you the facts about where a stock has been and what a company has done in the past, Trefis focuses entirely on the future.

Learn More